Excel Therapeutics’ Stock Price Skyrockets Amid COVID-19 Resurgence

Excel Therapeutics’ stock price has reached its upper limit, closing at 7,850 won on the 3rd, a 22.85% increase from the previous trading day.

The surge is attributed to growing expectations of increased demand for specimen transport media for virus diagnostic testing, driven by the recent resurgence of COVID-19.

As the sole producer of the transport media required for transporting samples from individuals tested for COVID-19, the company is poised to benefit from this trend.

Additionally, expectations of increased exports have contributed to the stock price hike. Excel Therapeutics has developed Cellker, a cell culture media, in just three years since its establishment, laying the groundwork for mass cell culturing.

Recently, the company signed a contract with a new drug development company to utilize Cellker in a global phase 3 clinical trial. This partnership is expected to lead to exports to 30 to 40 countries, resulting in hundreds of billions of won in export performance.

Excel Therapeutics, founded in September 2015, specializes in research, development, and production of cell culture media suitable for advanced biopharmaceuticals (CGT).

The company has established a cell-customized media development platform technology by incorporating the significance scoring data of media raw material candidate components by cell type and the know-how of the media development process.

The Ministry of Trade, Industry and Energy has recognized the badge development and manufacturing technology as a key strategic technology in the field of ‘key cell and material manufacturing technology for advanced biopharmaceutical manufacturing.’